Literature DB >> 21139096

Pancreatic cancer: will incremental advances begin to make a difference?

David C Holzman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21139096     DOI: 10.1093/jnci/djq521

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  2 in total

1.  IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells.

Authors:  Lei Cui; Yuezhen Deng; Yefei Rong; Wenhui Lou; Zhengfa Mao; Yuanyuan Feng; Dong Xie; Dayong Jin
Journal:  Tumour Biol       Date:  2011-11-26

2.  Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.

Authors:  Yoichi Toyama; Seiya Yoshida; Ryota Saito; Hiroaki Kitamura; Norimitsu Okui; Ryo Miyake; Ryusuke Ito; Kyonsu Son; Teruyuki Usuba; Takuya Nojiri; Katsuhiko Yanaga
Journal:  World J Surg Oncol       Date:  2013-01-09       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.